Ocular Surface Disease: Clinical Trials

6 trials for Ocular Surface Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 not yet recruiting, 1 unknown. 6 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Not yet recruiting 2, Unknown 1
Phase 21Completed 1

Follow Ocular Surface Disease: new trials by email Literature Review of Ocular Surface Disease trials Research Report on Ocular Surface Disease

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
PRO-240, Optive® - Dry Eye Disease, Dry Eye Sensation
Phase 1Not yet recruitingLaboratorios Sophia S.A de C.V.322027-07-302026-11-10
Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis
Probiotic, Placebo Drug - Probiotic, Ocular Surface Disease
Phase 1Not yet recruitingMohsen Pourazizi322025-02-012025-01-27
Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024
Group 1 drug, Group 2: Drug and placebo, Group 3: Drug and palcebo - Ocular Surface Symptom, Ocular Surface Disease
Phase 1UnknownMohsen Pourazizi1502024-10-302024-10-03
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
PRO-229, Lagricel® Ofteno PF - Dry Eye Disease, Ocular Surface Disease
Phase 1CompletedLaboratorios Sophia S.A de C.V.362024-05-162025-03-04
Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device
Restasis - Ocular Surface Disease
Phase 1 / Phase 2CompletedBoston Sight102021-07-152025-01-13
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
PP-001, Placebo - Keratoconjunctivitis, Ocular Surface Disease
Phase 1CompletedPanoptes Pharma GmbH452018-11-202024-01-12

Narrower conditions

Dry Eye Syndromes (2)  ·  Conjunctivitis, Allergic (1)  ·  Endophthalmitis (1)  ·  Eye Pain (1)  ·  Keratoconjunctivitis (1)

Broader conditions

Eye Diseases (5)  ·  Conjunctival Diseases (2)  ·  Conjunctivitis (2)  ·  Lacrimal Apparatus Diseases (2)  ·  Corneal Diseases (1)  ·  Eye Infections (1)  ·  Eye Manifestations (1)  ·  Hypersensitivity (1)  ·  Hypersensitivity, Immediate (1)  ·  Immune System Diseases (1)  ·  Infections (1)  ·  Keratitis (1)  ·  Neurologic Manifestations (1)  ·  Pain (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

CD5L protein, human (1)  ·  Cyclosporins (1)  ·  Pharmaceutical Preparations (1)  ·  Probiotics (1)

Sponsors

Laboratorios Sophia S.A de C.V. (2)  ·  Mohsen Pourazizi (2)  ·  Boston Sight (1)  ·  Panoptes Pharma GmbH (1)

Countries

Austria (1)  ·  Iran (1)  ·  Mexico (1)  ·  United States (1)

Top investigators

Daniel C Brocks, MD (1)  ·  Mohsen Pourazizi (1)